Cardiac Sarcoidosis Patient Healed by Anti-MAP Antibiotics

Cardiac Sarcoidosis Patient Healed by Anti-MAP Antibiotics

Cardiac Sarcoidosis Patient Healed by Anti-MAP Antibiotics

The author of this recent case study, Branko G. Celler, an Emeritus Professor at the University of New South Wales in Sydney, Australia, developed a particularly serious form of sarcoidosis in 2012. While sarcoidosis is a chronic disease characterized by the formation of granulomas in various organs, only a small portion of patients have cardiac involvement, which can lead to symptomatic conduction disturbances, ventricular arrhythmias, progressive heart failure and sudden death.

After a review of the literature, and believing his case to be mycobacterially related, he tested positive via Otakaro Pathways for mycobacteria. With the assistance of Prof. Thomas Borody, he began anti-mycobacterial therapy; at full strength consisting of 300 mg Rifabutin, 500 mg clarithromycin, 150 mg clofazimine and 800 mg metronidazole per day.

After a year of treatment, a repeat PET cardiac scan showed great improvement in both cardiac and pulmonary markers. This is the first report of the resolution of cardiac sarcoidosis using anti-mycobacterial antibiotics.

Read the full case study at the link below.

Celler B. Case Study: Cardiac sarcoidosis resolved with Mycobacterium avium paratuberculosis antibiotics (MAP). SVDLD [Internet]. 1Jul.2018 [cited 26Aug.2018];35(2):171-7.